鲁秀敏

个人简介

鲁秀敏,副教授,硕士生导师。重庆市遗传学会常务理事。1993.09-1997.07,获得西南大学作物与遗传育种专业学士学位;1997.07-2000.09,新疆农科院作物研究所从事科研工作;2000.09-2003.07,获得西南大学生物化学与分子生物学专业硕士学位;2005.09-2008.07,获得第三军医大学外科学专业博士学位。2003.07-至今,重庆理工大学药学与生物工程学院教师。在国内外重要刊物如HumMol Genet、Biomaterials、MolNeurobiol、Curr Pharm Design及BiomedPharmacother等发表论文57篇,发表论文共被他人引用270余次;授权发明专利2件;编写教材1部。

研究领域

基因工程药物;创伤免疫与修复

承担的主要项目

[1]靶向复合Nogo核酸疫苗的制备及其对损伤脊髓的免疫治疗研究,国家自然科学基金面上项目,2012.1-201

4.12,22万,主持。

[2] Nogo-66核酸疫苗接种对脊髓损伤的修复作用,重庆市教委科学技术研究项目,2010.1-2011.12,2万,主持。

[3] NTFs促进周围神经损伤修复分子机制的初步研究,国家重点实验室课题,2006.7-2007.12,5万,主持。

[4]雪旺细胞NF-kB在NTFs促神经损伤修复中的作用,重庆市自然科学基金计划项目,2004.4-2006.4,2万,主持。

[5]纳米金介导的GMCSF-Nogo复合核酸疫苗的构建及其对损伤脊髓的免疫治疗作用,国家重点实验室课题,2013.1-2014.12,21万,参与。

[6]p75NTR拮抗肽的制备及其阻抑NgR信号对损伤脊髓的修复作用,重庆市自然科学基金计划项目,2008.9-2011.9,3万,参与。

代表性成果

[1] Wang YT,Lu XM (Co-correspondingauthor), Zhu F, Huang P, Yu Y, Long ZY, Wu YM. Ameliorative effects of p75NTR-ED-Fcon axonal regeneration and functional recovery in spinal cord-injured rats. MolNeurobiol, 2015, 52(3):1821-1834.(SCI, IF 5.397)

[2]Lu XM, Wei JX, Xiao L, ShuYH, Wang YT. Experimental and clinical advances in immunotherapy strategies forspinal cord injury target on MAIs and their receptors. Curr Pharm Design, 2016,22(6): 728-737.(SCI, IF 3.052)

[3]Lu X, Su N, Yang J, Huang W,Li C, Zhao L, He Q, Du X, Shen Y, Chen L. Fibroblast growth factor receptor 1 regulatesthe differentiation and activation of osteoclasts through Erk1/2 pathway.Biochem Biophys Res Commun, 2009, 390 (3): 494-499.(SCI,IF 2.595)

[4] Fang SQ, Wang YT, Wei JX, Shu YH,Xiao L,Lu XM (Corresponding author). Beneficial effects of chlorogenicacid on alcohol-induced damage in PC12 cells. Biomed Pharmacother, 2016, 79: 254-262.(SCI, IF 2.326)

[5] Shu YH,Lu XM (Co-first author),Wei JX, Xiao L, Wang YT. Update on the role of p75NTR in neurologicaldisorders: A novel therapeutic target. Biomed Pharmacother, 2015, 76: 17-23.(SCI,IF 2.326)

[6] Wang YT,Lu XM (Co-correspondingauthor), Chen KT, Shu YH, Qiu CH. Immunotherapy strategies for spinal cord injury.Curr Pharm Biotechnol, 2015, 16(6): 492-505.(SCI, IF 1.802)

[7] Liu YJ, Zhou CY, Qiu CH,Lu XM(Co-corresponding author), Wang YT. Chlorogenic acid induced-apoptosis and inhibitionofproliferationin human acute promyelocytic leukemiaHL-60 cells. Mol Med Rep, 2013, 8 (4): 1106-1110.(SCI, IF 1.484)

[8]Lu XM, Shu YH, Qiu CH, ChenKT, Wang YT. Protective effects and anti-apoptotic role of nerve growth factoron spinal cord neurons in sciatic nerve-injured rats. Neurol Res, 2014, 36(9):814-823.(SCI,IF 1.439)

[9] Wang YT,Lu XM (Co-correspondingauthor), Shu YH, Xiao L, Chen KT. Selection of human p75NTR tag SNPs and itsbiological significance for clinical association studies. Biomed Mater Eng,2014, 24 (6): 3833-3839.(SCI, IF 1.091)

[10] Wang YT,Lu XM (Co-first author),Zhu F, Zhao M. The preparation of gold nanoparticles and evaluation of theirimmunological function effects on rats. Biomed Mater Eng, 2014, 24 (1): 885-892.(SCI, IF 1.091)

[11] Wang YT,Lu XM, Zhu F, HuangP, Yu Y, Zeng L, Long ZY, Wu YM. The use of a gold nanoparticle-based adjuvantto improve the therapeutic efficacy of hNgR-Fc protein immunization in spinalcord-injured rats. Biomaterials, 2011, 32(31): 7988-7998.(SCI, IF 7.404)

[12] Su N, Sun Q, Li C,Lu X, QiH, Chen S, Yang J, Du X, Zhao L, He Q, Jin M, Shen Y, Chen D, Chen L.Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Hum Mol Genet,2010, 19 (7): 1199-1210.(SCI, IF 8.058)

[13]肖岚,王永堂,位景香,舒亚海,鲁秀敏(通讯作者),余瑛.配对免疫球蛋白样受体B与神经再生.中国康复理论与实践,2016,22(5):544-547.

[14]陈开廷,王永堂,舒亚海,肖岚,鲁秀敏(通讯作者).以髓磷脂相关抑制因子及其受体为靶点的脊髓损伤免疫治疗策略研究.生命科学,2015,27(2):191-197.

[15]邱春红,陈开廷,王永堂,鲁秀敏(通讯作者).核酸疫苗的安全性及其优化策略研究.生命科学,2013,25(9):858-864.

[16]崔会会,邱春红,鲁秀敏(通讯作者).维甲酸诱导基因I的新功能.生命科学,2013,25(4):396-401.

[17]鲁秀敏,邱春红,崔会会,王永堂,伍亚民.基于Rho促进脊髓损伤修复的基础与临床研究.实用医学杂志,2012,28(22):3846-3848.